Regeneron jumps as third-quarter results beat expectations and margins improve

Regeneron Pharmaceuticals (REGN) is up 11.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The rally appears tied mainly to a strong third-quarter earnings beat, helped by a sharp increase in collaboration revenue tied to Dupixent and improved profitability. Investors also seemed encouraged by updated 2026 guidance that pointed to better gross margin and lower selling expenses, which can support stronger full-year earnings.

Details:

Regeneron posted third-quarter 2026 total revenue of $5.116 billion, up 36% from a year earlier, while non-GAAP diluted earnings per share rose to $20.07.

The company said Sanofi collaboration revenue stepped up because the Sanofi Development Balance had been fully repaid by the end of the second quarter, so it no longer reduced collaboration revenue in the third quarter.

Product trends were mixed but still supportive overall: global Dupixent sales grew 35%, EYLEA HD sales rose 63%, and Libtayo sales increased 44%, offsetting continued declines in legacy EYLEA.

Management also updated 2026 guidance, raising expected gross margin to about 80% on a GAAP basis and about 86% on a non-GAAP basis while lowering SG&A ranges.

Sources:

Regeneron Pharmaceuticals Investor Relations, Yahoo Finance, Boursorama

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$REGN Insider Trading Activity

$REGN insiders have traded $REGN stock on the open market 45 times in the past 6 months. Of those trades, 0 have been purchases and 45 have been sales.

Here’s a breakdown of recent trading of $REGN stock by insiders over the last 6 months:

ANDREW J MURPHY (Co-Chief Scientific Officer) has made 0 purchases and 27 sales selling 4,147 shares for an estimated $3,204,375.
MARION MCCOURT (EVP Commercial) has made 0 purchases and 2 sales selling 2,346 shares for an estimated $2,002,458.
KATHRYN GUARINI has made 0 purchases and 2 sales selling 800 shares for an estimated $660,000.
HUDA Y ZOGHBI sold 800 shares for an estimated $640,000
ARTHUR F RYAN has made 0 purchases and 13 sales selling 300 shares for an estimated $200,553.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive REGN Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$REGN Hedge Fund Activity

We have seen 642 institutional investors add shares of $REGN stock to their portfolio, and 679 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JPMORGAN CHASE & CO added 3,774,199 shares (+inf%) to their portfolio in Q2 2026, for an estimated $2,353,364,044
INVESCO LTD. added 2,216,187 shares (+128.5%) to their portfolio in Q2 2026, for an estimated $1,381,881,241
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 846,306 shares (+inf%) to their portfolio in Q2 2026, for an estimated $527,705,643
FMR LLC removed 686,228 shares (-45.2%) from their portfolio in Q2 2026, for an estimated $427,890,607
PRICE T ROWE ASSOCIATES INC /MD/ removed 647,818 shares (-29.8%) from their portfolio in Q2 2026, for an estimated $403,940,435
CAPITAL WORLD INVESTORS removed 604,075 shares (-42.6%) from their portfolio in Q2 2026, for an estimated $376,664,925
WELLINGTON MANAGEMENT GROUP LLP removed 567,372 shares (-30.9%) from their portfolio in Q2 2026, for an estimated $353,779,136

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$REGN Congressional Stock Trading

Members of Congress have traded $REGN stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $REGN stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. sold up to $15,000 on 05/15.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$REGN Analyst Ratings

Wall Street analysts have issued reports on $REGN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HSBC issued a "Buy" rating on 07/06/2026

To track analyst ratings and price targets for $REGN, check out Quiver Quantitative's $REGN forecast page.

$REGN Price Targets

Multiple analysts have issued price targets for $REGN recently. We have seen 13 analysts offer price targets for $REGN in the last 6 months, with a median target of $730.0.

Here are some recent targets:

Biren Amin from Piper Sandler set a target price of $854.0 on 07/09/2026
Matthew Harrison from Morgan Stanley set a target price of $730.0 on 07/08/2026
Gregory Renza from Truist Securities set a target price of $769.0 on 07/07/2026
Robert Wasserman from Benchmark set a target price of $185.0 on 07/07/2026
Brian Abrahams from RBC Capital set a target price of $696.0 on 07/07/2026
Carter Gould from Cantor Fitzgerald set a target price of $750.0 on 07/06/2026
Rajesh Kumar from HSBC set a target price of $880.0 on 07/06/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.